TAYLOR BALL: Open Payments
NPI 1457122855 · LAFAYETTE, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$682 in 36 payments from 10 companies in 2025. Trend: 2023 $0 · 2024 $958 · 2025 $682
Food & beverage: $682
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 18 | $275 |
| Janssen Biotech, Inc. | 5 | $159 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $51 |
| GENZYME CORPORATION | 2 | $45 |
| Ardelyx, Inc. | 2 | $41 |
| Lilly USA, LLC | 2 | $37 |
| Ipsen Biopharmaceuticals, Inc | 1 | $21 |
| Novo Nordisk Inc | 1 | $20 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $16 |
| Braintree Laboratories, Inc. | 1 | $16 |
Products named: TREMFYA, SKYRIZI, CREON, RINVOQ, ENTYVIO, DUPIXENT, IBSRELA, OMVOH.
Industry payments across LA — which companies pay providers there.
